keangkong
GLP-1 Specialist
- Member Since
- Sep 2, 2024
- Posts
- 1,331
- Likes Received
- 3,614
My health insurance pays a large of money for me to take Zepbound. Supposedly they pay about $650 every four weeks for it, although with pharmacy benefit managers and the weird way they do things, I know that it pays less for it. However, while you say that no one will pay for Zepbound, many individuals and insurance companies already are.![]()
OTP Exclusive: Lilly Has Been Quietly Exploring Alternative Avenues to Shut Down Tirzepatide Compounding
In an exclusive interview last night with Scott Brunner, CEO of the Alliance for Pharmacy Compounding, we uncovered a bombshell: Eli Lilly has been working quietly but diligently on additional means to remove compounded versions of tirzepatide—the active ingredient in Mounjaro and Zepbound—from...www.onthepen.com
They’ve been trying to say it’s a demonstrably difficult compound since August. But it’s obvious no one can afford it and by next year better drugs will be available so it’s almost like they don’t want people on it? What a truly weird way to drive people away. They could make it affordable and make so much more money. This drug costs $84 in Japan so it’s not like it’s costly to manufacture. Am I missing something here? Do they really think people will pay $1000 a month for it?
My lay opinion is that the FDA won't go along with semaglutide and tirzepatide being difficult to compound. They're actually quite easy to compound. Both Novo and Lilly submissions includes deaths reported to the FDA Federal Adverse Event Reporting System (FAERS), a system includes any reports of deaths made by anyone. No confirmation is required before being inputted into the data pool. Thus, to accept that compounded semaglutide caused many deaths, you'd also need to accept that Wegovy caused a larger number of deaths. (I haven't actually looked up the data on Zepbound, but I expect it to be similar.)